Knee Osteoarthritis Pipeline

DelveInsight’s, “Knee Osteoarthritis Pipeline Insight, 2026” report provides comprehensive insights about 55+ companies and 65+ pipeline drugs in Knee Osteoarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Knee Osteoarthritis Understanding

Knee Osteoarthritis Overview

Knee osteoarthritis (OA), also known as degenerative joint disease, is typically the result of wear and tear and progressive loss of articular cartilage. It is most common in the elderly. Knee osteoarthritis can be divided into two types, primary and secondary. Primary osteoarthritis is articular degeneration without any apparent underlying reason. Secondary osteoarthritis is the consequence of either an abnormal concentration of force across the joint as with post-traumatic causes or abnormal articular cartilage, such as rheumatoid arthritis (RA).

Osteoarthritis is typically a progressive disease that may eventually lead to disability. The intensity of the clinical symptoms may vary for each individual. However, they typically become more severe, more frequent, and more debilitating over time. The rate of progression also varies for each individual. Common clinical symptoms include knee pain that is gradual in onset and worse with activity, knee stiffness and swelling, pain after prolonged sitting or resting, and pain that worsens over time.

Articular cartilage is composed primarily of type II collagen, proteoglycans, chondrocytes, and water. Healthy articular cartilage constantly maintains an equilibrium between each of the components so that any degradation of cartilage is matched by synthesis. Healthy articular cartilage is thus maintained. In the process of osteoarthritis, matrix metalloproteases (MMPs), or degradative enzymes, are overexpressed, disrupting the equilibrium and resulting in an overall loss of collagen and proteoglycans. In the early stages of osteoarthritis, chondrocytes secrete tissue inhibitors of MMPs (TIMPs) and attempt to increase the synthesis of proteoglycans to match the degradative process. However, this reparative process is not enough. The loss in equilibrium results in a decreased amount of proteoglycans despite increased synthesis, increased water content, the disorganized pattern of collagen, and ultimately loss of articular cartilage elasticity. Macroscopically these changes result in cracking and fissuring of the cartilage and ultimately erosion of the articular surface.

Knee osteoarthritis is classified as either primary or secondary, depending on its cause. Primary knee osteoarthritis is the result of articular cartilage degeneration without any known reason. This is typically thought of as degeneration due to age as well as wear and tear. Secondary knee osteoarthritis is the result of articular cartilage degeneration due to a known reason.

The diagnosis of knee osteoarthritis is based on clinical evaluation supported by weight-bearing radiographic imaging, including standing anteroposterior, lateral, and patellar views, which accurately assess joint space narrowing and alignment. Typical radiographic features include joint space narrowing, osteophyte formation, subchondral sclerosis, and cysts. Management follows a stepwise approach, beginning with non-surgical strategies aimed at symptom relief, such as patient education, physical therapy, weight loss, activity modification, bracing, and pharmacologic treatments like NSAIDs and analgesics, along with selected intra-articular injections. If these measures fail, surgical options are considered based on disease severity and patient factors, including osteotomy or unicompartmental knee arthroplasty for localized disease, and total knee arthroplasty for advanced, multicompartment involvement, with the overall goal of reducing pain and improving function.

"Knee Osteoarthritis Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Knee Osteoarthritis pipeline landscape is provided which includes the disease overview and Knee Osteoarthritis treatment guidelines. The assessment part of the report embraces, in depth Knee Osteoarthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Knee Osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest Knee Osteoarthritis pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Knee Osteoarthritis Pipeline Report Highlights

• The Knee Osteoarthritis companies and academics are working to assess challenges and seek opportunities that could influence Knee Osteoarthritis R&D. The therapies under development are focused on novel approaches to treat/improve Knee Osteoarthritis.

Knee Osteoarthritis Emerging Drugs Analysis

This segment of the Knee Osteoarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Knee Osteoarthritis Emerging Drugs

SL-1002: Saol Therapeutics Inc

SL-1002 is a novel, chemoneurolytic injection, that utilizes Saol’s proprietary CYCLOPHLEXTM technology. It is a proprietary chemoneurolytic agent designed to destroy nerve tissue to block pain or spasticity signals. It is currently being developed for the treatment of chronic knee pain related to osteoarthritis and limb spasticity, both in the adult population in the United States. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Knee Osteoarthritis.

4P004: 4P-Pharma

4P004 is a pioneering, first-in-class Disease-Modifying Osteoarthritis Drug (DMOAD) developed by 4Moving Biotech as a GLP-1 analog for knee osteoarthritis. It is designed to be injected intra-articularly to reduce inflammation and structural damage. It has FDA Fast Track Designation and is currently in Phase IIa trials, with top-line results expected in early 2027. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Knee Osteoarthritis.

NCR100: Nuwacell Biotechnologies Co., Ltd.

NCR100 is an investigational cell therapy developed by Nuwacell Biotech Co., Ltd., based on induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (iMSCs). It is designed primarily for the treatment of knee osteoarthritis and represents the first iPSC-derived mesenchymal stem cell product approved for clinical trials in China. Mechanistically, NCR100 leverages the regenerative and immunomodulatory properties of mesenchymal stem cells, including tissue repair, anti-inflammatory effects, promotion of angiogenesis, and support of endogenous cell regeneration. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Knee Osteoarthritis.

BBM-A101: Belief BioMed (Beijing) Co., Ltd

BBM-A101 is an investigational, bio-engineered adeno-associated virus (AAV) vector gene therapy developed by Belief BioMed to treat knee osteoarthritis (KOA). Administered via intra-articular injection, it delivers a human anti-inflammatory protein gene to reduce pain and inflammation while potentially slowing disease progression. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Knee Osteoarthritis.

Further product details are provided in the report……..

Knee Osteoarthritis Therapeutic Assessment

This segment of the report provides insights about the different Knee Osteoarthritis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Knee Osteoarthritis

There are approx. 55+ key companies which are developing the therapies for Knee Osteoarthritis. The companies which have their Knee Osteoarthritis drug candidates in the most advanced stage, i.e. Phase III include, Saol Therapeutics Inc.

Knee Osteoarthritis Clinical Trial Phases

DelveInsight’s report covers around 65+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Knee Osteoarthritis Drug Route of Administration

Knee Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Knee Osteoarthritis Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Knee Osteoarthritis Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Knee Osteoarthritis Clinical Trial Activities

The Knee Osteoarthritis pipeline report provides insights into different Knee Osteoarthritis clinical trials within phase II, I, preclinical and discovery stage. It also analyses Knee Osteoarthritis therapeutic drugs key players involved in developing key drugs.

Knee Osteoarthritis Pipeline Development Activities

The Knee Osteoarthritis clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Knee Osteoarthritis drugs.

Knee Osteoarthritis Pipeline Report Insights

• Knee Osteoarthritis Pipeline Analysis
• Knee Osteoarthritis Therapeutic Assessment
• Knee Osteoarthritis Unmet Needs
• Impact of Knee Osteoarthritis Drugs

Knee Osteoarthritis Pipeline Report Assessment

• Knee Osteoarthritis Pipeline Product Profiles
• Knee Osteoarthritis Therapeutic Assessment
• Knee Osteoarthritis Pipeline Assessment
• Knee Osteoarthritis Inactive drugs assessment
• Knee Osteoarthritis MarketUnmet Needs

Discover actionable insights into the Knee Osteoarthritis market trends, epidemiology trends, and forecast through 2036 to stay ahead in emerging therapies.

Key Questions Answered In The Knee Osteoarthritis Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Knee Osteoarthritis drugs?
• How many Knee Osteoarthritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Knee Osteoarthritis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Knee Osteoarthritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Knee Osteoarthritis and their status?
• What are the key designations that have been granted to the emerging drugs?

Knee Osteoarthritis Key Players

• Saol Therapeutics Inc
• 4P-Pharma
• Nuwacell Biotechnologies Co., Ltd.
• Belief BioMed (Beijing) Co., Ltd
• Sanofi
• Pacira Pharmaceuticals, Inc
• Genascence Corporation
• Anterogen Co., Ltd.
• Avidence Therapeutics
• Cytonics Corporation
• CarthroniX, Inc.
• Calliditas Therapeutics
• ICM Co. Ltd.
• Addpharma Inc.
• Peptinov SAS
• Novartis
• Ageless Biotech, Inc.
• OrthoTrophix, Inc
• Nordic Bioscience
• Amzell
• CellSeed Inc.
• Doron Therapeutics Inc.
• Novo Nordisk A/S
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• Beijing Aosaikang Pharmaceutical Co., Ltd.

Knee Osteoarthritis Key Products

• SL-1002
• 4P004
• NCR100
• BBM-A101
• SAR446959
• FX201
• GNSC-001
• ANT-301
• AVD275
• CYT108
• CX-011
• SYN321
• ICM-203
• AD-211
• PPV-06
• RHH646
• OA-SYS
• TPX-100
• KBP-336
• AMZ001
• CLS2901C
• PTP-01
• NNC0487-0111
• HRS-2129
• ASKC200

Explore comprehensive insights into Knee Osteoarthritis epidemiology trends, patient population forecasts, and growth opportunities through 2034 for strategic decision-making.